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expiry of the original brand, from a third payer’s perspective,
based on the alendronate case. METHODS: The Belgian trade
name for alendronate is Fosamax® (patent expiry: April 2008).
The basis for reimbursement (reference price) for generics is set
by law at minus 30%. The originator company introduced
Fosavance® (ﬁxed combination with vitamin D—patent expiry:
2018) in July 2006. Using registered consumption data from
RIZIV, the evolution of the monthly expenses for alendronates
was considered and expected annual expenses were estimated
with or without the reimbursement of Fosavance®. RESULTS:
The monthly expenses for Fosamax® decreased from €2.7 Mio
prior to the reimbursement of Fosavance® to €1.4 M by July
2007. Simultaneously the expenses for Fosavance® increased to
€1.4 M. Only 52% of the market (in value) is left for generic
competition. The monthly opportunity savings are estimated to
be 30% of €1.4M (€0.52 M) instead of 30% of €2.7 M
(€0.81 M). The opportunity loss is therefore €3.5 M per year
assuming constant market value (137,500 patients treated with
alendronates in 2006). CONCLUSIONS: The alendronate
patent expiry and generic competition would theoretically have
generated an economy of 30% on the entire alendronate
market. The switch to the patent-protected ﬁxed combination
however shelters a substantial part of this market from generic
competition and from the effects of the off-patent reimburse-
ment policy. Therefore, this ‘life cycle management’ technique
jeopardizes the release of ﬁnancial resources and the creation of
budget headroom, essential for ﬁnancing the access to new
and/or innovative medicines. It should be considered as an
opportunity ‘lost’.
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OBJECTIVES: The Hungarian goverment allocates signiﬁcant
investment budget for hospital development between 2008–
2013. A cost-beneﬁt model was developed to assess the social
beneﬁt of public health care investments. We present the results
for a planned investment in a large district hospital with 1586
beds. METHODS: We considered the following long-term social
and ﬁnancial beneﬁts: 1) QALY gain and incremental costs from
new services; 2) cost savings and QALY gain from simpliﬁed
patient routes and reduced postoperative complication; 3)
improved technical efﬁciency of operation (e.g. matrix organiza-
tion); and 4) reduction of ﬁxed costs. Inncremental costs and
beneﬁts are calculated over a 15 year period. We employed 8%
discount rate for costs and 5% for QALYs. Health beneﬁts were
translated to monetary terms by assuming 40,000€/QALY gain
coversion rate. 250 HUF/1€ exchange rate was used in the
model. RESULTS: Our model estimated €8.1 million ﬁnancial
and €43.7 million social beneﬁt over 15 years from the €49.5
million investment. The Net Present Value of the hospital devel-
opment project is €7.5 million (including the remaining value of
assets after 15 years). The investment potentially improves the
sustainabilty of the hospital operation, as the annual net ﬁnancial
balance exceeds the annual cost of depriciation by €800,000.
CONCLUSIONS: Cost-beneﬁt analysis of public investment
projects improves the allocative efﬁciency of scarce resources.
Our model can assess the return on investemnt by capturing
long-term social and ﬁnancial beneﬁts and also the sustainability
of hospital operation. Prospective validation of the model is
necessary.
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OBJECTIVES: To describe the effect of patient’s morbidity load
in relation to resource utilization in Primary Care (measured by
pharmacy cost and visits) trough the retrospective application of
ACG in 23 Primary Care Health Centres from three Spanish
regions. METHODS: Multicentre, retrospective study based on
data from electronic records of patients seeking care during 2005
in the autonomous regions of Aragon, Balearics and Catalonia.
Principal measurements: universal variables (age, sex, health
service-family practice/paediatrics), variables of morbidity
(resource utilization bands [RUB]) and dependent variables
(visits, episodes and pharmacy cost). The ACG case-mix System
software (version 7.0; n = 106) classiﬁed subjects into a single
category for a given annual resource consumption. A log trans-
formation of dependent variables was carried out to reduce skew
ness of the distribution and make it close to normal. Statistical
software: SPSSWIN, p < 0.05. RESULTS: Study population:
286,450 (Aragon: 49.3%; Balearics: 23.2%; Catalonia: 27.5%),
annual coverage: 75.5% of the population, patient’s mean age:
42.9  23.6 years, percentage of female patients: 54.1%, mean
number of consultations: 7.3  7.1; 6.6  7.0 and 8.0  8.1
correspondingly, p < 0.001. Patient’s case-mix: 55.0% of the
study population was grouped into 10 ACG. A high variability
was observed among regions with differences in the average
values of RUB (2.9  0.8; 2.3  0.8; 2.4  0.8) and pharmacy
cost (€361.67; €242.01; 290.89), p < 0.001. The explanatory
power of the ACG classiﬁcation system was 30.7% (Ln: 41.2%)
for visits, 87.6% (Ln: 87.1%) for episodes and 21.3% (Ln:
39.9%) for pharmacy cost, p < 0.001. CONCLUSIONS: The
fact that patient’s morbidity load is adequately correlated with
attended consultations and pharmacy cost reinforces the appro-
priateness of the ACG system when associating clinical and eco-
nomic information from health care centers in Primary Care. In
consequence, case-mix adjustment must be considered for clini-
cal decision-making and ﬁnancial management in Primary Care.
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OBJECTIVES: Financial protection of the afﬁliated workers to
the Social Security Mexican Institute (IMSS) is one of its core
functions; however it also generates outlays to the health system.
This study estimates the associated cost to additional sick leave
days due to medical causes and/or due to inefﬁciencies on the
system. METHODS: A cost study was made from the perspective
of the institution through a prospective cohort of male and
female patients to whom it was prescribed temporal sick leave
days due to diseases not related to the work environment (general
disease), a follow-up was scheduled until their return to their
work place and the cost of medical attention was calculated; this
included ambulatory consult, drugs, lab exams, urgency service
assistance, surgery, hospital time and payment under the concept
of sick leave. All patients must have an estimation of the prob-
able number of recovery days, those who required additional
days were identiﬁed and the causes that triggered a longer lapse.
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